Skip to main content
Andrea Chipman on Muck Rack

Andrea Chipman

Nottingham, United Kingdom
As seen in: Newsweek, The Economist, The BMJ, Philips, Clinical Pharmacist, The Pharmaceutical Journal, Digital Health, CampdenFB, Financial Management, The Limbic
Covers:  Health and healthcare systems, business and finance
Doesn't Cover: Fitness technology
Freelance journalist, writer and editor covering health, emerging markets and a lot in between.

Get in touch with Andrea

Contact Andrea, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Andrea Chipman’s Biography

Read Full Bio →

Andrea Chipman has worked as a freelance journalist since 2004 and is based in Nottingham, England. She edits FORESIGHT Global Health, a publication focusing on non-communicable diseases, and has been a health writer for nearly a decade/ She has written about health, business and science policy for a range of publications including the Economist Intelligence Unit, the Wall Street Journal and Nature Magazine. She previously spent eight years as a financial reporter for Dow Jones Newswires, worki…

Andrea Chipman’s Journalist Portfolio

Historian reveals how babies starved to death before formula was invented

Historian reveals how babies starved to death before formula was invented

The recent shortages of baby formula in the U.S. have ignited social media commentary from breastfeeding advo…

View article →

View article →
The path to malaria elimination in sub-Saharan Africa

The path to malaria elimination in sub-Saharan Africa

About this report The path to malaria elimination in sub-Saharan Africa is an Economist Intelligence Unit rep…

View article →
Pandemic builds potential for better global health - FORESIGHT

Pandemic builds potential for better global health - FORESIGHT

The covid-19 pandemic has already transformed the world as we know it, upending policy priorities across mult…

View article →

Articles

Nipocalimab’s gMG benefits hold up long-term: trial

|
By Andrea Chipman
| The Limbic Verified
Long-term follow-up of the phase 3 Vivacity-MG3 trial has shown nipocalimab’s benefits in antibody-positive generalised myasthenia gravis (gMG) are sustained over time, researchers told the European Academy of Neurology 2026 Congress. Post-hoc analyses also showed symptom improvements held up even when patients caught common infections, offering reassurance about using the monoclonal antibody during periods when disease exacerbations are more likely.
Open in Who Shared Issue with article?

Severe pneumonia has three ‘pneumotypes’: study

|
By Andrea Chipman
| The Limbic Verified
Severe pneumonia may comprise three distinct “pneumotypes” with biological differences that could explain why some patients respond better to treatment and recover faster than others, new study findings suggest. The research by Cambridge University Hospitals in the UK involved patients with severe pneumonia treated in intensive care units. Investigators studied immune cells, inflammatory signals and gene activity from fluid collected from patients’ lungs.
Open in Who Shared Issue with article?

Dual therapy shows additive haemodynamic benefit pre‑BPA

|
By Andrea Chipman
| The Limbic Verified
Bridging therapy prior to balloon pulmonary angioplasty (BPA) in chronic thromboembolic pulmonary hypertension (CTEPH) is associated with improved haemodynamics, with differences between treatment strategies, researchers report.
Open in Who Shared Issue with article?
See all 470 licensed articles (501 Total)